The approval relies on positive data from the POTOMAC Phase III trial.

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...

Feb 8 (Reuters) - AstraZeneca AZN.L on Thursday forecast higher revenue and profit for 2024, betting on strong uptake of its infant RSV shot and resilient demand for its cancer and rare blood disorder ...

The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026.

This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical ...

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on AstraZeneca, with a price target of £160.00. Claim 55% Off TipRanks. Unlock trusted, data-b ...

Developer says clinic plan would support site's role as a national health innovation hub ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

Shares of AstraZeneca PLC AZN shed 1.64% to £132.14 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 10,373.51.

By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill ...